Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Journal article published in 2024 by
Laura C. Coates,
Robert Landewé,
Iain B. McInnes,
Philip J. Mease,
Christopher T. Ritchlin,
Yoshiya Tanaka,
Akihiko Asahina,
Frank Behrens 
,
Dafna D. Gladman,
Laure Gossec,
Ana-Maria Orbai,
Alice B. Gottlieb,
Richard B. Warren,
Barbara Ink,
Rajan Bajracharya
and other authors.
,
Dafna D. Gladman,
Laure Gossec,
Ana-Maria Orbai,
Alice B. Gottlieb,
Richard B. Warren,
Barbara Ink,
Rajan Bajracharya
and other authors.
